Cat­a­lyst shares jazzed by a new round of pos­i­tive re­sults for a rare neu­ro­mus­cu­lar dis­ease

Cat­a­lyst Phar­ma­ceu­ti­cals says it scored promis­ing da­ta from a tiny mid-stage study of its lead drug Fir­dapse in an ul­tra-rare neu­ro­mus­cu­lar dis­ease, set­ting up a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER